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Medication Use Evaluation of Dronedarone in Comparison to Amiodarone 
Adam Corey, PharmD Candidate, University of North Carolina Eshelman School of Pharmacy and Nita Johnston, PharmD, MS 
Transitions of Care Administrative Coordinator, Moses H. Cone Hospital 
 
 
Abstract 
Amiodarone is the most effective rhythm-control for atrial fibrillation, but produces serious potential side effects.  Dronedarone was 
designed to eliminate amiodarone toxicities, but increased the risk of mortality in clinical trials.  This medication use evaluation 
compares one year of dronedarone use with a matched cohort of amiodarone patients at a single hospital in Greensboro, NC.  Forty-
eight patients were included with an average age of 71.8 years and 37.5% female population.  No significant difference was found for 
the primary composite outcome of death, myocardial infarction, stroke, and systemic embolism (OR = 2.4, p = 0.148).  Likewise, no 
statistical significance was demonstrated between the two groups for QTc prolongation, hypothyroidism, liver dysfunction or 
maintenance of normal sinus rhythm.  In conclusion, the clinical decision process demonstrated no increased risk of death or other 
adverse events in the use of dronedarone. 
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Introduction 
Atrial fibrillation (AF), the most frequently diagnosed cardiac 
arrhythmia, affects 2 million American patients.   The growing 
number of elderly patients is expected to further increase the 
rate of AF.  AF increases a patient’s morbidity and mortality 
through an increased risk in stroke, embolism and heart 
failure.  Management of AF includes three angles of 
treatment including cardioversion, anticoagulation and rate 
control.  Chemical cardioversion utilizes antiarrhythmic 
medications to maintain normal sinus rhythm by restoring 
the balance of ion channels in the cardiac muscle tissue.1   
The most effective drug of rhythm control, amiodarone, 
maintains normal sinus rhythm in 65% of patients within the 
first year.2 However, amiodarone use is complicated by 
numerous side effects such as hepatic and pulmonary 
toxicities, changes in thyroid metabolism and other toxicities 
associated with long term use.3 
 
Dronedarone was designed as the “non-iodinated benzofuran 
derivative” of amiodarone to expected to maintain efficacy 
and improve tolerability.1 In the ATHENA Trial of 4600 
patients, dronedarone decreased cardiovascular and 
arrhythmic death, but demonstrated no effect on all-cause 
mortality.4 While originally thought to be a safer alternative 
to amiodarone, dronedarone has significant black box 
warnings and contraindications.  Use of dronedarone remains 
limited to paroxysmal or persistent AF in patients without 
symptomatic heart failure.5 These limitations were 
determined based on two clinical trials.  In the ANDROMEDA 
trial, 627 patients with heart failure and no AF received  
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dronedarone or placebo.  The trial was terminated early as 
the risk of mortality doubled in the dronedarone group.6 In 
PALLAS, patients with permanent AF had their trial stopped 
due to a doubling of the risk of stroke, clots, myocardial 
infarctions and death.7  
 
Due to the concerning increased risk of mortality in multiple 
clinical trials, the use of dronedarone has decreased 
dramatically due to the limited indicated patient population.  
While amiodarone remains the most effective option, 
toxicities leave clinicians searching for a safer alternative.  
This retrospective, matched cohort study aims to determine 
the rate of adverse events in dronedarone use against 
matching patients receiving amiodarone in the clinical 
setting. 
 
Methods 
In this IRB-approved medication utilization evaluation, 
patients taking dronedarone and amiodarone were compared 
for serious adverse events, efficacy and readmissions.  The 
study occurred at a single-center in Greensboro, North 
Carolina.  All patients receiving an inpatient order of 
dronedarone during the calendar year 2015 were included.  
Matching amiodarone patients were chosen by selecting the 
same age, same sex and the nearest admission date to the 
dronedarone patient.   
 
The data collected included that patient’s age, and sex, date 
of admission(s), medications, death (and cause of death if 
applicable), myocardial infarction, stroke, symptoms of heart 
failure, most recent LVEF, electrocardiogram rhythm, QTc 
interval, and thyroid status.   
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The primary objective of this study was the composite 
outcome of all-cause mortality, myocardial infarction, stroke 
and systemic embolism.  Secondary objectives included each 
aspect of the primary composite individually, as well as 
cardiovascular mortality, maintenance of normal sinus 
rhythm, QTc prolongation greater than 450 milliseconds, liver 
toxicity assessed by either AST or ALT greater than 40 mg/dL, 
hypothyroidism, and number of readmissions within the next 
year of hospitalization. 
 
 
 
Results 
Between Jan 1, 2015 and December 31, 2015, dronedarone 
was ordered 40 times for 24 different patients.  During the 
same period, amiodarone was ordered 2,682 times.  Through 
matched cohort pairing, two groups of 24 patients were of 
the same average age (71.8 years) and the same distribution 
of males to females (37.5% female), as seen in Table 1.  
Patients in the dronedarone group had lower serum 
creatinine, were more likely to be on anticoagulation, and 
had fewer patients with symptomatic heart failure and 
reduced ejection fraction less than 35%. 
 
 
 
 
Table 1.  Patient Demographic Information 
 
  Dronedarone Amiodarone 
Total Patients (n) 24 24 
Age (years) 71.8 71.8 
Sex (Female) 37.5% 37.5% 
Serum Creatinine (mg/dL) 1.2 1.7 
Anticoagulation 19 14 
Symptomatic Heart Failure 3 14 
LVEF ≤35% 2 11 
 
 
 
 
In the primary outcome shown in Table 2, 5 dronedarone 
patients (20.8%) and 12 amiodarone patients (50.0%) 
experienced an outcome event of death, stroke, myocardial 
infarction or systemic embolism.  The odds ratio of 2.4 
showed a trend of reduction in events with dronedarone, but 
failed to meet statistical significance (p = 0.148).   
 
For secondary outcomes, no comparisons reached statistical 
significance as some events trended to demonstrate benefit.  
Fewer patients died in the dronedarone group (3) compared 
to the amiodarone group (8), with an odds ratio of 2.67 (p = 
0.183).  No patients in the dronedarone group died of a 
cardiovascular cause, while 6 amiodarone patients met this 
criteria (OR = 13, p=0.086).  Both groups had the same 
number of strokes (1 vs 1, OR = 1, p = 1) and a similar number 
of myocardial infarctions (1 in dronedarone vs 2 in 
amiodarone, OR = 2, p = 0.582).  One patient on amiodarone 
experienced a systemic embolism compared to none in the 
dronedarone group (OR = 3, p = 0.508).   
 
 
 
 
Both medications increased the QTc interval, with 9 
dronedarone patients having a QTc ≥ 450 milliseconds and 17 
amiodarone groups (OR = 1.89, p = 0.206).  Both groups had 
four patients with elevated liver function enzymes (OR = 1, p 
= 1).  Six dronedarone patients were diagnosed with 
hypothyroidism, while 9 amiodarone patients met the criteria 
(OR = 1.5, p = 0.5).  In terms of efficacy, 14 dronedarone 
patients and 15 amiodarone groups were in normal sinus 
rhythm (OR = 1.07, p = 0.883).  Patients in the dronedarone 
group were readmitted 1.7 ± 1.4 times during the next year, 
as 1.4 ±1.3 readmissions were seen in the amiodarone group 
(Difference 0.3, p = 0.446). 
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Table 2.  Safety and Efficacy Comparison of Dronedarone Patients and Matched Cohort 
 
  
Dronedarone Amiodarone 
Odds Ratio p Value 
Events Percent Events Percent 
Composite of Death, Stroke, MI, 
and Embolism 5 20.8% 12 50.0% 2.4 0.148 
All-Cause Mortality 3 12.5% 8 33.3% 2.67 0.183 
Cardiovascular Death 0 0.0% 6 25.0% 13 0.086 
Stroke 1 4.2% 1 4.2% 1 1 
MI 1 4.2% 2 8.3% 2 0.582 
VTE 0 0.0% 1 4.2% 3 0.508 
Prolonged QT (>450 ms) 9 37.5% 17 70.8% 1.89 0.206 
Normal Sinus Rhythm 14 58.3% 15 62.5% 1.07 0.883 
Elevated LFTS (≥40) 4 16.7% 4 16.7% 1 1 
Hypothyroidism 6 25.0% 9 37.5% 1.5 0.5 
Readmissions per Patient 1.7 ±1.4 1.4 ±1.3 Diff = 0.3 0.446 
 
 
Discussion 
This single-center, matched cohort study compared patients 
receiving dronedarone or amiodarone.  In terms of the 
primary outcome of the composite including death, stroke, 
myocardial infarction and systemic embolism, the two groups 
had no statistical difference despite 12 events occurring in 
the amiodarone group and 5 events in the dronedarone 
group.  Likewise, no secondary outcomes produced a 
statistically significant difference.  There was no difference 
between the two groups in terms of all-cause mortality, 
stroke, myocardial infarction, systemic embolism.  While six 
amiodarone patients experienced cardiovascular death 
compared to zero dronedarone patients, the outcome was 
not significant.  The ANDROMEDA and PALLAS trials were 
both terminated early due to increased mortality of the 
dronedarone group compared to placebo.6,7 Because of these 
trials, the dronedarone group contained no patients with 
permanent AF and only three patients with symptomatic 
heart failure.  Dronedarone was discontinued in all three 
heart failure patients in accordance with the 
contraindications found in the package insert.5 The clinical 
process decreases the mortality risk of the dronedarone 
group by excluding the patients identified to be at a higher 
risk of death.  Meanwhile, the amiodarone patients had a 
higher rate of heart failure which has a higher risk of 
mortality and a potentially explains the disparity in mortality 
outcomes between the two groups. 
 
In literature, amiodarone consistently remains the most 
effect agent at maintaining normal sinus rhythm at 
approximately 65%.2 This study matches the historical results 
for amiodarone treatment and 62.5% of patients 
demonstrated efficacy.  However, this study found the 
success of dronedarone at 58.3% compared to the 35% 
efficacy of the ATHENA trial.4 These results may not reflect 
the overall efficacy of dronedarone in patients.  This patient 
population primarily represented those continuing the 
medication during a hospital admission.  Only one patient 
initiated dronedarone while an inpatient.  The majority of 
dronedarone patients were continuing the medication 
because they had demonstrated previous efficacy. 
 
As dronedarone was designed to reduce the toxicities 
associated with amiodarone, this study monitored the 
common adverse events.  Amiodarone is known to cause liver 
and lung toxicities, and the use of dronedarone is 
contraindicated in patients that have experienced these 
complications with prior amiodarone use.3,5 During the study, 
no cases of pulmonary toxicity were observed in either group.  
The rates of liver dysfunction were the same at 16.7% for 
both groups.  The sensitivity of liver dysfunction was set at 
any elevation of AST or ALT greater than 40 mg/dL.  Several of 
the patients with liver damage were known to be caused by 
excessive alcohol use and not considered to be due to the 
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antiarrhythmic agent.  Another common amiodarone 
complication is changes in thyroid metabolism – both 
hyperthyroidism and hypothyroidism.  The rates of 
hypothyroidism were determined by the diagnosis on the 
problem list, prescription use of levothyroxine on the 
medication list, or elevated TSH levels on lab results.  The rate 
of hypothyroidism in the amiodarone group was 37.5% 
compared to 25% in the dronedarone group.  Two 
dronedarone patients had hyperthyroidism directly related to 
prior amiodarone use, potentially confounding the results.  
Similarly, this information correlates the rate of 
hypothyroidism with the two medications without attempting 
to establish causality.  Patients may have been diagnosed 
with hypothyroidism prior to the development of AF and not 
as a result of medications. 
 
Both amiodarone and dronedarone are known to increase 
the risk of QT prolongation due to the mechanism of action 
on ion channels in myocardial tissues.3,5 Both groups 
demonstrated an elevation of the QTc interval, as 70.8% of 
amiodarone patients and 37.5% of dronedarone patients had 
an extended interval at admission.  Meanwhile, no cases of 
Torsades de Pointes were noted during the study timeframe, 
consistent with the rarity of the complication and the rates of 
Torsades in patients taking amiodarone and dronedarone.  
 
No differences were found between the rates of readmission 
between the amiodarone and dronedarone groups.  The 
dronedarone group had slightly more admissions (1.7) 
compared to the amiodarone group (1.3), but the difference 
was not statistically significant.  These readmissions looked 
only at admissions and discharges from one year after the 
patient’s first hospital encounter.  The reasons for admission 
were not noted and therefore it cannot be determined if the 
medications played a role in the need for readmission.  
However, the amiodarone group average was driven by a 
single patient with 9 readmissions who died during the final 
encounter.  When that patient is excluded, the amiodarone 
rate drops to 1.1 ± 0.9, but the difference remains 
nonsignificant (p = 0.084). 
 
This medication use evaluation attempted to compare the 
outcomes of patients that received dronedarone and 
amiodarone during an inpatient encounter.  Few studies exist 
directly comparing the two medications, especially in the 
clinical setting.  As a retrospective study, the authors made 
no attempt to guide prescriber decisions providing 
generalizability to the results.  One limitation to this study is 
the small sample size.  By utilizing the data at a single center 
during a single year, the number of dronedarone patients was 
limited.  Another limitation could be the matching process 
which compared age, sex and date of admission.  No effort 
was made to control for severity of disease nor to exclude 
patients with heart failure.  This disparity may have allowed 
for an amiodarone population with more progressive 
diseases, however the results remained nonsignificant.   
 
Direct comparisons between dronedarone and amiodarone 
remain rare.  More studies, potentially involving more 
centers, should measure the mortality and efficacy of current 
clinical practices.  In the current study, several differences 
were identified between the two groups but each failed to 
meet statistical significance with a small sample size.  An 
expanded patient population may potentially identify 
differences in cardiovascular mortality, QTc prolongation, and 
hypothyroidism. 
 
Conclusion 
This single-center, matched cohort study of clinical use of 
dronedarone and amiodarone during hospital admission 
found no statistical difference the rates of mortality, stroke, 
myocardial infarction and systemic embolism.  Clinical 
decision-making which preselects the dronedarone 
population may prevent the serious potential adverse events 
in the treatment of AF. 
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